Table 4.
Mean differences in cognitive trajectories according to the baseline NRI in the MAPT (n = 712)
| characteristic | Omega-3 PUFA | Serum 25-OH-D | Plasma HCy | ß coefficient estimate | SE | P |
|---|---|---|---|---|---|---|
| NRI, baseline | ||||||
| 0 | 0 | 0 | 0 | 0 | — | — |
| 1 (HCy) | 0 | 0 | 1 | −0.1168 | 0.0775 | .1320 |
| 1 (D) | 0 | 1 | 0 | −0.1880 | 0.0863 | .0296 |
| 1 (O3) | 1 | 0 | 0 | −0.0917 | 0.1544 | .5526 |
| 2 (HCy + D) | 0 | 1 | 1 | −0.1114 | 0.0828 | .1785 |
| 2 (O3 + HCy) | 1 | 0 | 1 | −0.0809 | 0.0949 | .3943 |
| 2 (O3 + D) | 1 | 1 | 0 | −0.1025 | 0.1412 | .4680 |
| 3 (O3 + D + HCy) | 1 | 1 | 1 | −0.3859 | 0.1006 | .0001 |
| NRI × time (y) | ||||||
| 0 | 0 | 0 | 0 | 0 | — | — |
| 1 (HCy) | 0 | 0 | 1 | −0.0383 | 0.0240 | .1121 |
| 1 (D) | 0 | 1 | 0 | −0.0603 | 0.0267 | .0243 |
| 1 (O3) | 1 | 0 | 0 | −0.0142 | 0.0538 | .7924 |
| 2 (D + HCy) | 0 | 1 | 1 | −0.0969 | 0.0253 | .0001 |
| 2 (O3 + HCy) | 1 | 0 | 1 | −0.0712 | 0.0300 | .0179 |
| 2 (O3 + D) | 1 | 1 | 0 | −0.0872 | 0.0449 | .0525 |
| 3 (O3 + D + HCy) | 1 | 1 | 1 | −0.1098 | 0.0328 | .0008 |
NOTE. Model adjusted for baseline age, gender, education, trial arm, trial arm × time interaction; primary outcome is MAPT cognitive composite Z score. NRI increases by one point for each of the following: omega-3 PUFA (O3) ≤4.82 wt%; serum 25-OH-D (D) ≤20 ng/mL; and plasma HCy ≥14 μmol/L.
Abbreviations: NRI, nutritional risk index; MAPT, multidomain Alzhemier prevention trial; PUFA, polyunsaturated fatty acid; Serum 25-OH-D, serum 25-hydroxyvitamin D; HCy, homocysteine; SE, standard error; D, vitamin D; O3, omega-3 PUFA intervention.